IVIG in Acute Ischemic Stroke: A Pilot Study (IVIG/AIS)
|ClinicalTrials.gov Identifier: NCT01628055|
Recruitment Status : Withdrawn (difficult recruitment and new black box warning for IVIG)
First Posted : June 26, 2012
Last Update Posted : November 11, 2013
The purpose of the study is to evaluate the ability of IVIG to affect the rate of progression of brain ischemia, as evidenced by neuroimaging.
The results of an ongoing epidemiological study indicate that patients with primary immunodeficiency (PID) on IVIG replacement therapy have an overall prevalence of stroke that is 5 times less than in the general population. Even more striking is the absence of stroke in IVIG-treated PID patients over 65, while in the same general population age group the stroke prevalence goes up to 8.1%. This suggests that the degree of stroke protection correlates with the length of IVIG treatment, since older PID patients have been treated with IVIG significantly longer than younger ones.
|Condition or disease||Intervention/treatment||Phase|
|Ischemic Stroke||Biological: Privigen Other: Normal Saline||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||IVIG in Acute Ischemic Stroke: A Pilot Study|
|Study Start Date :||March 2013|
|Estimated Primary Completion Date :||August 2013|
|Actual Study Completion Date :||September 2013|
The IVIG preparation to be used is 10% liquid (Privigen). IVIG will be applied at a dose of 1.0g/kg, which is approximately 1/2 of the optimal dose used for other immuno/inflammatory indications. The infusion will start at 0.5 ml/kg/hr for the first 30 minutes, to watch for the signs of hypersensitivity to immunoglobulins, and then increased to 2.5 ml/kg/hr, two times slower than the recommended rate indicated in the product package insert (5 ml/kg/hr). Such a low, single dose has not been associated with hyperviscosity and together with a slow infusion will safeguard against occurrence of adverse events related to IVIG infusions. They will receive a total of 1g/kg and depending on patient's weight, it will take between 3.5 to 4+ hours to infuse that amount.
10% liquid intravenous immunoglobulin at a single dose of 1.0g/kg, run at 0.5ml/kg/hr for the first 30 minutes, then increased to 2.5ml/kg/hr until complete (~3-4 hours depending on weight).
Placebo Comparator: Normal Saline
The placebo is the normal saline. Since saline solution will be infused at the volume equivalent to that in which the intended dose of immunoglobulin molecules will be delivered, the placebo (comparator) arm will also serve as a control for the volume of fluid infused to the treatment arm participants.
Other: Normal Saline
Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents. The pH is 5.0 (4.5 to 7.0).
It contains 9 g/L Sodium Chloride with an osmolarity of 308 mOsmol/L and 154 mEq/L Sodium and Chloride.
The infusion will start at 0.5 ml/kg/hr for the first 30 minutes and then increased to 2.5 ml/kg/hr for 3-4 hours.
Other Name: 0.9% Sodium Chloride Solution
- Post-IVIG DWI/PI mismatch measurement [ Time Frame: 3 days ]Decrease in the size of post IVIG necrotic area relative to baseline values and percent of penumbra saved, defined by neuroimaging as DWI/PI mismatch.
- Favorable clinical outcome [ Time Frame: 90 days ]Favorable clinical outcome at Day 90, which requires fulfillment of all three of the following criteria: improvement in NIHSS of 8 points or more from baseline; modified Rankin scale (mRS) score of 0-2 points; and Barthel index (BI) of 75-100
- Clinical outcome measure by NIHSS [ Time Frame: 3 days ]Clinical outcome measured by change in NIHSS scores will be also examined on Day 3
- Active complement fragment levels [ Time Frame: 90 days ]Levels of active complement fragments, C3a, C5a, C5b-9 and C4d at Day 0 and post-IVIG and Day 90.
- Adverse Events [ Time Frame: 90 days ]Incidence in adverse events.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01628055
|United States, Virginia|
|Inova Health Systems; Inova Fairfax Hospital|
|Falls Church, Virginia, United States, 22042|
|Study Director:||Beverly C Walters, MD||Inova Health Systems|
|Study Chair:||Milan Basta, MD||BioVisions, Inc.|
|Principal Investigator:||Jack Cochran, MD||Inova Health Systems|